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Abstract
Neomycin, an aminoglycoside, is use at farm level for Escherichia coli treatment of piglets postweaning diarrhea, with 40% 
of unsuccessfully treatment due to the antimicrobial resistance. To overcome this situation, veterinarians use colistin also call 
polymyxin E, but this antibiotic is not homologated in Canada, even if it seems to be effective against E.coli. The described 
resistance to polymyxin is associated to a modification of the LPS core and the lipid A regions in the bacteria. For Salmo-
nella, those modifications are associated to the two components system PmrA-PmrB. This system is known in E.coli but not 
yet reported to be implicated in colistin resistance. The neomycin resistance is linked to enzymatic modifications associated 
to genes located on plasmids. This study has for objectives to investigate the acquisition of colistin resistance and study the 
transfer of neomycin resistance between E.coli strains and other enterobacteria. E.coli O149 strains isolated from clinical 
cases (2008 to 2011) were used and susceptibility testing of strains was performed by the disk diffusion method. E-test and 
a micro-dilution method were used to determine the minimal inhibitory concentration (MIC) of colistin and neomycin re-
spectively. All tested strains had a MIC higher than 128 ppm for neomycin whereas MICs were between 0.064 to 0.128 ppm 
for colistin, indicating that all strains were resistance to neomycin but all susceptible to colistin. In these isolates, neomycin 
antimicrobial resistance genes aac(3)-IV, apkA1 and aphA2 have been detected using PCR. Conjugation experiments are 
presently being performed. Colistin natural mutants (n=22) were created through serial passages on LB agar with 25xMIC. 
Sequencing of the PmrA-PmrB region of these mutants was performed to identify mutations. Three PmrA and seven PmrB 
mutations were for the first time reported in E.coli O149. Others mutants are still under investigation for other possible re-
sistance mechanism.
Introduction
Escherichia coli O149 is the major cause of post-weaning diarrhea with an important economic impact. Veterinarians use 
neomycin, an aminoglycoside for treatment of this condition. Unfortunately near 40% of the treatments are unsuccessfully 
due to E.coli resistance to this antibiotic (Maynard et al., 2003). The most frequently associated mechanism of resistance is 
by enzymatic modification, acetylation and phosphorylation, of the neomycin. Three genes are mostly associated with neo-
mycin resistance; acc(3)-IV, apk(3’)-I, aph(3’)-II and most of the time, we find those genes on plasmids of different size (4 
to 93kb) (Shaw et al., 1993). To overcome this situation, veterinarians use colistin sulphate (CS), a polypeptide antimicrobial 
also call polymyxin E, but this antibiotic is not authorize in Canada even if it seems to be effective against E.coli, because it 
is use in human medicine for Pseudomonas aeruginosa in kystic fibrosis. In other countries, this polypeptide antibiotic is 
recommended for the oral therapy of intestinal infections in pig. The target of CS is the Gram negative bacteria lipopolysac-
charide (LPS) molecule by a cationic interaction leading to a displace of cation magnesium Mg2+ and calcium Ca2+ causing 
a leakage of intracellular contents and bacterial death (Wang and Quinn, 2010). Resistance to colistin have been reported in 
Salmonella sp. by the two components system PmrAB. This system is associated with a modification of the LPS by adding a 
L-ara4N group to LPS core causing a reduction of negative charge, leading to a less negative LPS charge (Boll et al., 1994). A 
mutation in those genes could lead to a constitutively of the system leading to a CS resistance by decreases the cationic liaison 
between CS and LPS. Therefore, the aim of this study was to first evaluate the in vitro acquisition of CS resistance and second 
to assess the in vitro transfer of neomycin resistance.
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Material & method
Eight strains of E.coli O149 isolated from clinical cases (2008 to 2011) by ECL lab were selected for neomycin resistance. 
Susceptibility testing was performed by the disk diffusion method. Briefly, a dilution corresponding to a McFarland 0,5 was 
made in saline solution and uniformly plated on Mueller-Hinton (MH) agar, disks were aseptically added and plates were 
incubated overnight at 37°C. E-test was used to determine the MIC of colistin, briefly an uniformly plate was made with a 
dilution corresponding to a McFarland 0,5 on MH agar, E-test bands were aseptically added and plates were incubated over-
night at 37°C. For neomycin MIC, a micro-dilution method was used. Briefly, in sterile 96-well polystyrene microtitre plates, 
serial double dilution were made in MH broth from 128 mg/L to 0.25 mg/L. Each well was inoculated with approximately 
5x104 CFU/ml of E.coli strains in MH broth. The MIC was determined as the lowest concentration that resulted in inhibition 
of bacterial growth. In all MIC experiments, ATCC 25922 E.coli strain was used as control. For the  8 E. coli strains, PCR was 
used to determine the presence of antimicrobial resistance genes acc(3)-IV (F-GTGTGCTGCTGGTCCACAGC R-AGTT-
GACCCAGGGCTGTCGC), apk3’)-I (F-ATGGGCTCGCGATAATGTC R-CTCACCGAGGCAGTTCCAT) and aph(3’)-II 
(F-GAACAAGATGGATTGCACGC R-GCTCTTCAGCAATATCACGG).
Colistin mutants were created by incu-
bation of each strain overnight at 37°C, 
on Luria-Bertani broth (LB) with a colis-
tin concentration under the MIC. Serial 
passages were done on LB with 25xMIC 
for mutants selection.  Mutant DNA was 
extracted by standard boiling method. 
Amplification of genes pmrA and pmrB 
was performed by PCR using respectively 
primers F-CAAACTTGCAGGAGAGT-
GAG R-GCTGATCAGCTCAAACACCA 
and F-GGCTTTGGCTATATGCTGGT 
R-TTAACTACCGTGTTCAGCGT. PCR 
products were purified with PureLink® 
PCR Purification Kit (Invitrogen, Canada). 
Sequencing was performed by Sanger 
(Genome Québec). Alignments of se-
quence were done with Clustal X software.
Results
For the first objective on antimicrobial re-
sistance, all tested strains had a MIC higher 
than 128 ppm for neomycin whereas MICs 
were between 0.064 to 0.128 ppm for colis-
tin, indicating that all strains were resistant 
to neomycin but all susceptible to colis-
tin. PCR detection of neomycin resistance 
genes showed that apk(3’)-I was found in 
six strains. Strains 1000 and 2000 have two 
resistance genes respectively acc(3)-IV, ap-
k(3’)-I and acc(3)-IV, aph(3’)-II. (Fig 1)
Mutants were created (n=24) and sequenc-
ing showed 7 different mutation sites in 
pmrAB region leading to a colistin resis-
tance phenotype. Most of the mutations 
were found in mutants from E.coli ATCC 
25922 strain and these mutations were ob-
served in the pmrB gene. (Fig 2)
Strain 
ID Years Virotype
MIC  
Neomycin 
(µg/ml)
Resistance 
genes
MIC 
Colistin 
(µg/ml)
1000 2008 LT:STb:Paa:F4 512  acc(3)-IV, apk(3’)-I
0,064-
0,094
2000 2009 LT:STb:East1:F4 128 acc(3)-IV, aph(3’)-II
0,094-
0,125
3000 2009 LT:STb:Paa:F4 128 apk(3’)-I 0,047-0,064
4000 2009 LT:STb:Paa:F4 128  apk(3’)-I 0,094
5000 2010 LT:STb:East1:F4 128 apk(3’)-I 0,125
7000 2010 LT:STb:F4  256 apk(3’)-I 0,125
8000 2010 LT:STb:East1:Paa:F4  512 apk(3’)-I 0,064
Fig 1: Table of seven strains of E.coli O149 isolated from field with years of 
isolation, virotype, MIC to neomycin (µg/ml), MIC to colistin (µg/ml) and 
neomycin resistance genes
Mutant ID Gene Genotype MIC (µg/ml)
E.coli Lab strain ATCC 25922
0004 pmrA A80V 6
0001 pmrA N128I 6
0001 pmrA S144G 6
0001 pmrB D65E 6
0003 pmrB T98M 12
0006 pmrB V103G 3
O149 field strain causing post-weaning diarrhea
5001 pmrB V87E 3-4
2003 pmrB F145Y 6
2003 pmrB D148Y 6
7003 pmrB D148V 8
Fig 2: Table of E.coli mutants colistin resistant with the mutation genes, the 
genotype and the MIC of colistin in (µg/ml). A: Alanine, V: Valine, N: Aspar-
agine, I: Isoleucine, T: Threonine, M: Methionine, G: Glycine, E: Glutamate, 
D: Aspartate
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Discussion
Study of colistin resistance
This study is the first to report exact mutation in pmrAB genes leading to colistin resistance in E.coli O149 field strains and 
E.coli ATCC 25922 strain. In another study (Sun et al., 2009), pmrAB mutations were identified for Salmonella sp. In our 
study, mutants had higher MIC values (30 to 80x) comparatively to Salmonella mutants (2 to 35x) suggesting that the site of 
mutation in pmrAB is probably linked to the degree of resistance. We also create mutants without a pmrAB mutation sug-
gesting another mechanism of resistance. Other genes have been reported to have a higher expression in a bile salt medium 
leading to colistin resistance (Kus et al., 2011). The arn operon genes which are involved in the synthesis and transport of 
the L-ara4N subunit (Wang and Quinn, 2010) and  acrAB genes who are involved in a multidrug efflux system are potential 
other genes implicated in the colistin resistance without a pmrA or pmrB mutation.
Conclusion
This study showed mutations in pmrAB genes leading to colistin resistance in E.coli strains. A better understanding of the 
mechanism of resistance to colistin is needed for a better use of this antibiotic and avoid therapeutic practices having an im-
pact of antimicrobial resistance of E.coli associated to postweaning diarrhea or other disease. Further studies are on going to 
characterized mutations not associated to prmA / prmB genes.
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